From Adipose Tissue to Endothelial Cells—Pleiotropic Role of Vaspin in Pathogenesis of Metabolic and Cardiovascular Diseases

Background: Vaspin (also known as serpinA12) is a recent discovery among adipokines. It plays a significant role in obesity-related conditions, many of which are classified as chronic, inflammatory or lifestyle diseases. Due to its anti-inflammatory and insulin-sensitizing properties, vaspin has been investigated as a biomarker and potential therapeutic agent. Methods: A literature review was conducted using the MEDLINE and SCOPUS databases using the phrases “vaspin” and “serpinA12” to summarize the most recent and influential research concerning vaspin’s mechanisms and influence on various tissues. Results and Conclusions: Vaspin is notably involved in metabolic syndrome, and it is generally associated with mitigating conditions like insulin resistance and obesity-related chronic inflammation. In addition, its beneficial effects on endothelial and smooth muscle cells under hyperglycemic and hyperlipidemic conditions are also well documented. There is growing evidence that vaspin positively impacts cardiovascular health, reducing the risk of ischemic stroke and the development of atherosclerosis. Moreover, some studies suggest a direct influence of vaspin on the central nervous system, with its administration shown to reduce the expression of neuropeptide Y, a key regulator of food intake. Many of the reviewed sources highlight vaspin not only as a possible biomarker but also as a promising therapeutic candidate. However, despite intensive research on vaspin over the past 20 years, there are significant disparities between animal and in vitro studies versus human studies. A further limitation in the field is the lack of standardization in research methodologies, which contributes to inconsistent and sometimes contradictory results.